Global pharmaceutical companies acquire radiopharmaceuticals
By Son, Hyung-Min | translator Kang, Shin-Kook
24.05.28 05:19:29
°¡³ª´Ù¶ó
0
Lily¡¤AstraZeneca¡¤Novartis acquired companies specializing in radiopharmaceuticals
Domestic biopharmaceutical companies have also begun development¡¦FutureChem has successfully entered a Phase 2 trial
The high interest in radiopharmaceuticals has led to investments by pharmaceutical companies. Last year and this year, Lily invested KRW 3.5 trillion in a company developing radiopharmaceuticals. Global pharmaceutical companies, including AstraZeneca, Novartis, and BMS, have acquired companies developing radiopharmaceuticals and entered the market. In South Korea, FutureChem and Dong-A ST are also developing radiopharmaceuticals and exploring opportunities for technology transfer and commercialization potential.
Radiopharmaceuticals work by delivering radioactive isotopes into the body, and then the isotopes release radio waves when reaching cancer cells, destroying cancer organs. Radiopharmaceuticals are
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)